 |
|
Melanoma Trial Results
1. Researchers Shut Off Immune Cell Inhibition, Causing Tumor Shrinkage and Autoimmunity in Patients With Metastatic Melanoma
(Posted: 06/23/2003) - Scientists at the National Cancer Institute (NCI) have found a new method for modifying the immune system of cancer patients to induce cancer regression. Inhibiting a molecule known as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which has a critical role in regulating the immune response, can enable the immune system to attack some patients' tumors, the scientists report in the Proceedings of the National Academy of Sciences*.
2. High-Dose Interferon Prolongs Time to Recurrence in Melanoma
(Updated: 10/02/2001) - High-dose interferon alfa-2b significantly prolongs the time before melanoma recurs compared to low-dose interferon or no therapy, according to the findings of a large, randomized clinical trial.
3. Similar Survival Rates Found for Eye Cancer Therapies
(Posted: 07/12/2001) - Researchers with the Collaborative Ocular Melanoma Study (COMS) have found that the survival rates for two alternative treatments for primary eye cancer -- radiation therapy and removal of the eye -- are about the same.
4. Interferon Superior to a GMK Vaccine in Preventing Melanoma Relapse
(Posted: 05/04/2001) - High-dose interferon proved superior to a GMK ganglioside vaccine, a potentially promising cancer therapy, in protecting high-risk patients against a recurrence of their melanoma, according to research from a multicenter clinical trial published in the May 1, 2001, Journal of Clinical Oncology.
5. Chemoimmunotherapy No Better Than Combination Chemotherapy Alone for Metastatic Melanoma
(Posted: 11/10/1999) - A prospective randomized clinical trial at the National Cancer Institute finds that aggressive treatment for metastatic melanoma that combines chemotherapy drugs with immunotherapy agents yields survival results no better than that of treatment with combination chemotherapy alone.
|
|
|
